[go: up one dir, main page]

WO1996013594A8 - Tumor-specific antibody fragments, fusion proteins, and uses thereof - Google Patents

Tumor-specific antibody fragments, fusion proteins, and uses thereof

Info

Publication number
WO1996013594A8
WO1996013594A8 PCT/US1995/013811 US9513811W WO9613594A8 WO 1996013594 A8 WO1996013594 A8 WO 1996013594A8 US 9513811 W US9513811 W US 9513811W WO 9613594 A8 WO9613594 A8 WO 9613594A8
Authority
WO
WIPO (PCT)
Prior art keywords
provides
fusion proteins
lewisy
antibodies
regions
Prior art date
Application number
PCT/US1995/013811
Other languages
French (fr)
Other versions
WO1996013594A1 (en
Inventor
Ira Pastan
Itai Benhar
Eduardo A Padlan
Sun-Hee Jung
Byungkook Lee
Mark Willingham
David Fitzgerald
Ulrich Brinkmann
Lee Pai
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/331,398 external-priority patent/US5608039A/en
Priority claimed from US08/331,397 external-priority patent/US5981726A/en
Priority claimed from US08/331,396 external-priority patent/US5889157A/en
Application filed by Us Health filed Critical Us Health
Priority to JP8514718A priority Critical patent/JPH10508202A/en
Priority to AU41355/96A priority patent/AU717611B2/en
Priority to EP95939599A priority patent/EP0796334A1/en
Publication of WO1996013594A1 publication Critical patent/WO1996013594A1/en
Publication of WO1996013594A8 publication Critical patent/WO1996013594A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention provides for recombinant single chain antibodies capable of specifically binding to a LewisY-related carbohydrate antigen and fusion proteins comprising these antibodies. More particularly, the invention provides for single chain Fv (ScFv) regions of the monoclonal antibodies B1, B3, and B5, humanized single chain Fv regions of B1, B3, and B5, and fusion proteins comprising these scFv regions. The invention also provides for a number of stabilizing mutations of the LewisY-binding monoclonal antibody B3. In addition, the invention provides for methods of detecting cells bearing a LewisY antigen in a patient and for methods of killing or inhibiting the growth of cells bearing a LewisY antigen in a patient. The invention also provides for a method of improving the binding affinity of antibodies lacking a serine at position 95 of the V¿H? region that involves mutating position 95 to a serine.

Description

FOR THE PURPOSES OF INFORMATION ONLY
Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.
AT Austria GB United Kingdom MR Mauritania
AU Australia GE Georgia MW Malawi
BB Barbados GN Guinea NE Niger
BE Belgium GR Greece NL Netherlands
BF Burkina Faso HU Hungary NO Norway
BG Bulgaria IE Ireland NZ New Zealand
BJ Benin IT Italy PL Poland
BR Brazil JP Japan PT Portugal
BY Belarus KE Kenya RO Romania
CA Canada KG Kyrgystan RU Russian Federation
CF Central African Republic KP Democratic People's Republic SD Sudan
CG Congo of Korea SE Sweden
CH Switzerland KR Republic of Korea SI Slovenia
CI Cδte d'lvoire KZ Kazakhstan SK Slovakia
CM Cameroon LI Liechtenstein SN Senega!
CN China LK Sri Lanka TD Chad cs Czechoslovakia LU Luxembourg TG Togo cz Czech Republic LV Latvia TJ Tajikistan
DE Germany MC Monaco TT Trinidad and Tobago
DK Denmark MD Republic of Moldova UA Ukraine
ES Spain MG Madagascar US United States of America
FI Finland ML Mali UZ Uzbekistan
FR France MN Mongolia VN Viet Nam
GA Gabon
PCT/US1995/013811 1994-10-28 1995-10-26 Tumor-specific antibody fragments, fusion proteins, and uses thereof WO1996013594A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP8514718A JPH10508202A (en) 1994-10-28 1995-10-26 Tumor-specific antibody fragments, fusion proteins, and uses thereof
AU41355/96A AU717611B2 (en) 1994-10-28 1995-10-26 Tumor-specific antibody fragments, fusion proteins, and uses thereof
EP95939599A EP0796334A1 (en) 1994-10-28 1995-10-26 Tumor-specific antibody fragments, fusion proteins, and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/331,396 1994-10-28
US08/331,398 1994-10-28
US08/331,397 1994-10-28
US08/331,398 US5608039A (en) 1990-10-12 1994-10-28 Single chain B3 antibody fusion proteins and their uses
US08/331,397 US5981726A (en) 1990-10-12 1994-10-28 Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof
US08/331,396 US5889157A (en) 1990-10-12 1994-10-28 Humanized B3 antibody fragments, fusion proteins, and uses thereof

Publications (2)

Publication Number Publication Date
WO1996013594A1 WO1996013594A1 (en) 1996-05-09
WO1996013594A8 true WO1996013594A8 (en) 2000-04-06

Family

ID=27406791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/013811 WO1996013594A1 (en) 1994-10-28 1995-10-26 Tumor-specific antibody fragments, fusion proteins, and uses thereof

Country Status (4)

Country Link
EP (1) EP0796334A1 (en)
AU (1) AU717611B2 (en)
CA (1) CA2203236A1 (en)
WO (1) WO1996013594A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
WO2000026394A1 (en) * 1998-10-31 2000-05-11 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Variants of humanized anti-carcinoma monoclonal antibody cc49
AU2002324973A1 (en) * 2001-09-14 2003-04-01 Fraunhofer-Gesellschaft Zur Forderung Der Angewandandten Forschung E.V. Immunoglobulin having particular framework scaffold and methods of making and using
CA2420494A1 (en) * 2003-02-28 2004-08-28 Universite De Sherbrooke Ca 125 tumor antigen function and therapeutic uses thereof
CA2490659C (en) 2002-06-28 2014-08-19 Syed V. S. Kashmiri Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
CU23403A1 (en) 2003-04-23 2009-08-04 Centro Inmunologia Molecular RECOMBINANT ANTIBODIES AND FRAGMENTS RECOGNIZING GANGLIOSIDE N-GLICOLIL GM3 AND ITS USE FOR DIAGNOSIS AND TUMOR TREATMENT
WO2005021594A2 (en) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675413B2 (en) * 1991-09-30 1997-02-06 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Recombinant immunotoxins

Also Published As

Publication number Publication date
AU4135596A (en) 1996-05-23
WO1996013594A1 (en) 1996-05-09
EP0796334A1 (en) 1997-09-24
AU717611B2 (en) 2000-03-30
CA2203236A1 (en) 1996-05-09

Similar Documents

Publication Publication Date Title
WO1997020575A8 (en) Targeted adenovirus vectors
WO1997025042A8 (en) Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x
WO1997017980A8 (en) Treatment of cardiomyopathy by removal of autoantibodies
WO1996001622A8 (en) New oral pharmaceutical formulation containing magnesium salt of omeprazole
WO1996013594A8 (en) Tumor-specific antibody fragments, fusion proteins, and uses thereof
US5965133A (en) Self-assembling multimeric nucleic acid constructs
EP0367644B1 (en) Nucleotide sequence codings for a protein with urea reactivity
WO1997006318A8 (en) Sound-damping partition
WO1998016421A8 (en) Aircraft based sensing, detection, targeting, communications and response apparatus
US20070218494A1 (en) Branched polymer lables as drag-tags in free solution electrophoresis
WO1998040762B1 (en) Image-directed active range finding system
CH647870A5 (en) METHOD FOR ANALYZING A DETERMINED NUCLEIC ACID SEQUENCE OR FRAGMENT AND MEANS FOR CARRYING OUT THIS METHOD.
WO1994024204A3 (en) Composition for a cover material of a golf ball
Rouault et al. Influence of altered transcription on the translational control of human ferritin expression.
RU2005141341A (en) Polynucleotides cognate antigen STEM CELLS IN PROSTATE (PSCA), and the encoded MI protein (peptide), hybridomas and transgenic animals for the production of antibody, compositions for treatment, prevention, diagnosis and prognosis CANCER BASED THEREON (VERSIONS) METHOD FOR DETERMINING OF PRESENCE IN THE SAMPLED STUDY, METHOD FOR GENERATING AN IMMUNE RESPONSE, METHOD FOR DELIVING A CYTOTOXIC OR DIAGNOSTIC AGENT TO A CELL, METHOD FOR INHIBITING CANCER CELL GROWTH FROM THEIR USE
Sontheimer et al. Three novel functional variants of human U5 small nuclear RNA
Yamazoe et al. Sequential binding of SeqA protein to nascent DNA segments at replication forks in synchronized cultures of Escherichia coli
Redmond et al. A serine protease (CCP1) is sequestered in the cytoplasmic granules of cytotoxic T lymphocytes.
Lae et al. Clusterin is widely expressed in systemic anaplastic large cell lymphoma but fails to differentiate primary from secondary cutaneous anaplastic large cell lymphoma
WO1997020810A8 (en) Process for the preparation of 1-aryl-1-cyanocyclobutane derivatives
Baran et al. The modifier of Min 2 (Mom2) locus: embryonic lethality of a mutation in the Atp5a1 gene suggests a novel mechanism of polyp suppression
Navaglia et al. Helicobacter pylori cytotoxic genotype is associated with peptic ulcer and influences serology
WO2002037114A1 (en) Agent for detecting cancer's ability to metastasize
AU2000234142B2 (en) Method for providing the transmission characteristics of a microphone arrangement and microphone arrangement
KR19990087627A (en) Method for Inhibiting Methylthioadenosine Phosphorylase Deficiency Intracellular Adenillosuccinate Synthetase Activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase in:

Ref country code: CA

Ref document number: 2203236

Kind code of ref document: A

Format of ref document f/p: F

Ref document number: 2203236

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995939599

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995939599

Country of ref document: EP

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 21/96 UNDER (30) REPLACE "28.10.95" BY "28.10.94"

WWW Wipo information: withdrawn in national office

Ref document number: 1995939599

Country of ref document: EP